- Home
- AHR vs RARE Comparison
AHR vs RARE Comparison
Compare AHR & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AHR
- RARE
- Stock Information
- Founded
- AHR 2013
- RARE 2010
- Country
- AHR United States
- RARE United States
- Employees
- AHR N/A
- RARE N/A
- Industry
- AHR
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- AHR
- RARE Health Care
- Exchange
- AHR NYSE
- RARE Nasdaq
- Market Cap
- AHR 4.2B
- RARE 4.2B
- IPO Year
- AHR 2024
- RARE 2014
- Fundamental
- Price
- AHR $27.32
- RARE $42.59
- Analyst Decision
- AHR Buy
- RARE Strong Buy
- Analyst Count
- AHR 8
- RARE 15
- Target Price
- AHR $26.13
- RARE $93.13
- AVG Volume (30 Days)
- AHR 1.3M
- RARE 634.2K
- Earning Date
- AHR 02-27-2025
- RARE 02-13-2025
- Dividend Yield
- AHR 3.66%
- RARE N/A
- EPS Growth
- AHR N/A
- RARE N/A
- EPS
- AHR N/A
- RARE N/A
- Revenue
- AHR $2,005,322,000.00
- RARE $560,230,000.00
- Revenue This Year
- AHR N/A
- RARE $19.26
- Revenue Next Year
- AHR $9.49
- RARE $36.92
- P/E Ratio
- AHR N/A
- RARE N/A
- Revenue Growth
- AHR 9.88
- RARE 29.01
- 52 Week Low
- AHR $12.81
- RARE $37.02
- 52 Week High
- AHR $29.99
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- AHR 41.94
- RARE 44.76
- Support Level
- AHR $26.61
- RARE $41.73
- Resistance Level
- AHR $28.57
- RARE $44.98
- Average True Range (ATR)
- AHR 0.89
- RARE 1.72
- MACD
- AHR -0.15
- RARE -0.04
- Stochastic Oscillator
- AHR 22.30
- RARE 18.03
About AHR AMERICAN HEALTHCARE REIT INC
American Healthcare REIT Inc is a healthcare-focused real estate investment trust. It owns a diversified portfolio of clinical healthcare real estate properties, focusing primarily on medical office buildings, skilled nursing facilities, senior housing, hospitals, and other healthcare-related facilities. They have four reportable business segments: integrated senior health campuses, outpatient medical, triple-net leased properties and SHOP. It generates majority of revenue through Integrated Senior Health Campuses segment.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.